http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018149978-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2817954cd008bcd609a4c4eb49050be |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5055 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2018-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30ad754331b2c11b6bd058e23e3693c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06bbe4f49488a4fc71009c2d50300e87 |
| publicationDate | 2018-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018149978-A1 |
| titleOfInvention | ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS |
| abstract | The present invention relates to a method for determining whether a compound has the capability of inhibiting elF5a activation, comprising (a) contacting a sample comprising cells being capable of differentiating into M2 macrophages with the compound under conditions that allow for the differentiation of cells into M2-type macrophages in the absence of the compound; and (b) quantifying in the sample the cells having a M2-phenotype, wherein a reduction of the number of cells having a M2-phenotype as compared to a control sample not contacted with the compound indicates that the compound has the capability of inhibiting elF5a activation. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020227385-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113133995-A |
| priorityDate | 2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.